{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:08:10Z","timestamp":1740107290957,"version":"3.37.3"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T00:00:00Z","timestamp":1588896000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T00:00:00Z","timestamp":1588896000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100003493","name":"Gemeinn\u00fctzige Hertie-Stiftung","doi-asserted-by":"publisher","award":["HertiP1150063"],"award-info":[{"award-number":["HertiP1150063"]}],"id":[{"id":"10.13039\/501100003493","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003000","name":"Stichting MS Research","doi-asserted-by":"publisher","award":["14-358e"],"award-info":[{"award-number":["14-358e"]}],"id":[{"id":"10.13039\/501100003000","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1007\/s00415-020-09880-7","type":"journal-article","created":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T06:02:41Z","timestamp":1588917761000},"page":"2599-2602","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Application of \u201cMentzer\u2019s PML case definition\u201d to natalizumab-treated patients in the setting of strict MRI-based pharmacovigilance"],"prefix":"10.1007","volume":"267","author":[{"given":"Martijn T.","family":"Wijburg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clemens","family":"Warnke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joep","family":"Killestein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mike P.","family":"Wattjes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,5,8]]},"reference":[{"key":"9880_CR1","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/S1474-4422(18)30040-1","volume":"17","author":"EO Major","year":"2018","unstructured":"Major EO, Yousry TA, Clifford DB (2018) Pathogenesis of progressive multifocal leukoencephalopathy and risks associated with treatments for multiple sclerosis: a decade of lessons learned. Lancet Neurol 17:467\u2013480","journal-title":"Lancet Neurol"},{"key":"9880_CR2","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1212\/WNL.0b013e31828c2fa1","volume":"80","author":"JR Berger","year":"2013","unstructured":"Berger JR, Aksamit AJ, Clifford DB et al (2013) PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section. Neurology 80:1430\u20131438","journal-title":"Neurology"},{"key":"9880_CR3","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1136\/jnnp-2018-318261","volume":"90","author":"MT Wijburg","year":"2019","unstructured":"Wijburg MT, Warnke C, Barkhof F, Uitdehaag BMJ, Killestein J, Wattjes MP (2019) Performance of PML diagnostic criteria in natalizumab-associated PML: data from the Dutch-Belgian cohort. J Neurol Neurosurg Psychiatry 90:44\u201346","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"9880_CR4","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1136\/jnnp-2012-302478","volume":"83","author":"D Mentzer","year":"2012","unstructured":"Mentzer D, Prestel J, Adams O et al (2012) Case definition for progressive multifocal leukoencephalopathy following treatment with monoclonal antibodies. J Neurol Neurosurg Psychiatry 83:927\u2013933","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"9880_CR5","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1001\/jamaneurol.2018.0094","volume":"75","author":"MT Wijburg","year":"2018","unstructured":"Wijburg MT, Kleerekooper I, Lissenberg-Witte BI et al (2018) Association of progressive multifocal leukoencephalopathy lesion volume with JC virus polymerase chain reaction results in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis. JAMA Neurol 75:827\u2013833","journal-title":"JAMA Neurol"},{"key":"9880_CR6","doi-asserted-by":"publisher","first-page":"e2232","DOI":"10.1212\/WNL.0000000000007451","volume":"92","author":"K Blankenbach","year":"2019","unstructured":"Blankenbach K, Schwab N, Hofner B, Adams O, Keller-Stanislawski B, Warnke C (2019) Natalizumab-associated progressive multifocal leukoencephalopathy in Germany. Neurology 92:e2232\u20132239","journal-title":"Neurology"},{"key":"9880_CR7","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1136\/jnnp-2017-316886","volume":"89","author":"MP Wattjes","year":"2018","unstructured":"Wattjes MP, Wijburg MT, van Eijk J et al (2018) Inflammatory natalizumab-associated PML: baseline characteristics, lesion evolution and relation with PML-IRIS. J Neurol Neurosurg Psychiatry 89:535\u2013541","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"9880_CR8","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1136\/jnnp-2016-315298","volume":"88","author":"C Warnke","year":"2017","unstructured":"Warnke C, Wijburg MT, Hartung HP, Killestein J, Adams O, Wattjes MP (2017) Application of the CSF JCV antibody index to early natalizumab-associated progressive multifocal leukoencephalopathy. J Neurol Neurosurg Psychiatry 88:1092\u20131094","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"9880_CR9","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1002\/ana.24153","volume":"76","author":"C Warnke","year":"2014","unstructured":"Warnke C, von Geldern G, Markwerth P et al (2014) Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol 76:792\u2013801","journal-title":"Ann Neurol"},{"key":"9880_CR10","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1002\/ana.25437","volume":"85","author":"G Dalla Costa","year":"2019","unstructured":"Dalla Costa G, Martinelli V, Moiola L et al (2019) Serum neurofilaments increase at progressive multifocal leukoencephalopathy onset in natalizumab-treated multiple sclerosis patients. Ann Neurol 85:606\u2013610","journal-title":"Ann Neurol"},{"key":"9880_CR11","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1002\/ana.25523","volume":"86","author":"FC Loonstra","year":"2019","unstructured":"Loonstra FC, Verberk IMW, Wijburg MT et al (2019) Serum neurofilaments as candidate biomarkers of natalizumab associated progressive multifocal leukoencephalopathy. Ann Neurol 86:322\u2013324","journal-title":"Ann Neurol"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-020-09880-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-020-09880-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-020-09880-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,7]],"date-time":"2021-05-07T23:49:18Z","timestamp":1620431358000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-020-09880-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,8]]},"references-count":11,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["9880"],"URL":"https:\/\/doi.org\/10.1007\/s00415-020-09880-7","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"type":"print","value":"0340-5354"},{"type":"electronic","value":"1432-1459"}],"subject":[],"published":{"date-parts":[[2020,5,8]]},"assertion":[{"value":"30 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"MTW does not report any competing interest. CW has received speaking fees (institutional only) or research support from Novartis, Biogen, Roche and Sanofi Genzyme. JK has received consultancy fees from Merck-Serono, Teva, Biogen, Genzyme and Novartis. MPW has received speaker or consultancy fees from Bayer, Biogen, Biologix, Celgene, Genilac, Imcyse, IXICO, Medison, Merck-Serono, Novartis, Sanofi Genzyme, Roche, Teva, UCB Pharma.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Software application.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"We obtained a waiver from our local institutional review board stating that the requirements of the Medical Research Involving Human Subjects Act did not apply and that official IRB approval was not mandatory. Written informed consent was obtained from all participants for the use of the clinical, laboratory and imaging data for research and teaching purposes.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was obtained from all participants for the use of the clinical, laboratory and imaging data for research and teaching purposes. Written informed consent was obtained from all participants for publishing the data.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}